Vyome Holdings, Inc. HIND
1.78 USD +0.01 (+0.49%)
Nov 3, 2026, 3:15 PM EST
1.77 Day range 1.84
1.62 52-week range 6.33
- YTD
- -48.26%
- 1 year
- -71.79%
- Market cap
- 12.49M
- EPS (ttm)
- 1.78
- P/E ratio
- 1.00
- YTD return
- -48.26%
- 1-year return
- -71.79%
- Volume
- 3.11K
- Avg volume
- 13.01K
- Open
- 1.81
- Previous close
- 1.77
- Day's range
- 1.77 – 1.84
- 52-week range
- 1.62 – 6.33
1Y -4.39 (-71.15%)
Financials — quick view
HIND Revenue — quarterly 26.95K
HIND Net income — quarterly -685.56K
HIND EPS — quarterly -0.09
News
Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School 
Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market 
Vyome Holdings' ReShape Lifesciences Has Received A Notice Of Allowance For A U.S. Patent Titled "VAGUS NERVE NEUROMODULATION FOR THE TREATMENT OF THE HYPOGLYCEMIC STATE". 
Vyome Holdings Appoints Jerry Leonard As CFO, Succeeding Robert Dickey IV, Who Served As Interim CFO Since August 2025 
Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer 
Chardan Capital Initiates Coverage On Vyome Holdings with Buy Rating, Announces Price Target of $3.5 
Vyome Appoints Jerry Leonard As CFO On August 27, 2026 
Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet 
12 Health Care Stocks Moving In Friday's After-Market Session - China National Intellectual Property Administration Grants Vyome Patent Chinese Patent No. ZL 2021 1 0758695.X
Your note
Sign in to keep a note on HIND — it syncs with the Stock Master app.